Improving patient compliance with hypertension treatment: Mission possible?

Current Vascular Pharmacology

Volumn 8, Issue 6, 2010, Pages 804-807

  Chrostowska, Marzena ^a   Narkiewicz, Krzysztof ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Cardiovascular; Compliance; Hypertension; Treatment

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; DRUG WITHDRAWAL; HUMAN; HYPERTENSION; MONOTHERAPY; MORBIDITY; MORTALITY; PATIENT COMPLIANCE;

EID: 78649341983     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016110793563799     Document Type: Article

References (30)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data.Lancet 2005; 365: 217-23.
2. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. Selected major risk factors and global and regional burden of disease.Lancet 2002; 360: 1347-60.
3. Lawes CM, Vander Hoorn S, Rodgers A.; International Society ofHypertension. Global burden of blood-pressure-related disease,2001. Lancet 2008; 371: 1513-8.
4. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatmentand control in five European countries, Canada, and theUnited States. Hypertension 2004; 43: 10-7.
5. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalenceand blood pressure levels in 6 European countries, Canada,and the United States. JAMA 2003; 289: 2363-9.
6. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwideprevalence of hypertension: a systematic review. J Hypertens 2004; 22: 11-9.
7. Erdine S. How well is hypertension controlled in Europe? Eur SocHypertens Sci Newsl 2007; 8: 1-2.
8. He J, Muntner P, Chen J, Roccella EJ. Factors associated withhypertension control in the general population of the United States.Arch Intern Med 2002; 162: 1051-8.
9. Cifkova R, Kawecka-Jaszcz K. The scope of hypertension. BloodPress 2005; 14 (Suppl 2): 3-5.
10. Wang YR, Alexander GC, Stafford RS. Outpatient hypertensiontreatment, treatment intensification, and control in Western Europeand the United States. Arch Intern Med 2007; 167: 141-7.
11. Chobanian AV. The hypertension paradox more uncontrolleddisease despite improved therapy. N Engl J Med 2009; 361: 878-87.
12. Wang YR. Lack of effect of guideline changes on hypertensioncontrol for patients with diabetes in the U.S., 1995-2005. DiabetesCare 2007; 30: 49-52.
13. Ryden L, Waeber B, Ruilope LM, et al. The management of thetype 2 diabetic patient with hypertension too late and too little:suggested improvements. Blood Press 2008; 17: 250-9.
14. Jamerson K, Weber MA, Bakris GL, et al.; ACCOMPLISH TrialInvestigators. Benazepril plus amlodipine or hydrochlorothiazidefor hypertension in high-risk patients. N Engl J Med 2008; 359:2417-28.
15. Hedner T, Kjeldsen SE, Narkiewicz K. Health economy of themetabolic syndrome pandemic. Blood Press 2005; 14: 131-2.
16. Leal J, Luengo-Fernandez R, Gray A, Petersen S, Rayner M. Economicburden of cardiovascular diseases in the enlarged EuropeanUnion. Eur Heart J 2006; 27: 1610-9.
17. Redon J, Brunner HR, Ferri C, Hilgers KF, Kolloch R, van Montfrans G. Practical solutions to the challenges of uncontrolled hypertension:a white paper. J Hypertens 2008; 26: S1-14.
18. Bangalore S, Shahane A, Parkar S, Messerli FH. Compliance andfixed-dose combination therapy. Curr Hypertens Rep 2007; 9: 184-9.
19. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherenceto prescribed antihypertensive drug treatments: longitudinalstudy of electronically compiled dosing histories. BMJ 2008; 336:1114-7.
20. Parati G, Bilo G. Practical aspects of treatment discontinuation andadherence. J Hypertens 2009; 27 (Suppl 2): S18-21.
21. Corrao G, Zambon A, Parodi A, et al. Discontinuation of andchanges in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens 2008; 26:819-24.
22. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-97.
23. Christensen A, Christrup LL, Fabricius PE, et al. The impact of anelectronic monitoring and reminder device on patient compliancewith antihypertensive therapy: a randomized controlled trial. J Hypertens 2010; 28: 194-200.
24. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines forthe management of arterial hypertension: The Task Force for theManagement of Arterial Hypertension of the European Society ofHypertension (ESH) and of the European Society of Cardiology(ESC). J Hypertens 2007; 25: 1105-87.
25. Parati G, Stergiou GS, Asmar R, et al., ESH Working Group onBlood Pressure Monitoring. European Society of Hypertensionguidelines for blood pressure monitoring at home: a summary reportof the Second International Consensus Conference on HomeBlood Pressure Monitoring. J Hypertens 2008; 26: 1505-26.
26. Parati G, Omboni S, Albini F, et al.; TeleBPCare Study Group.Home blood pressure telemonitoring improves hypertension controlin general practice. The TeleBPCare study. J Hypertens 2009; 27:198-203.
27. Schroeder K, Fahey T, Ebrahim S. Interventions for improvingadherence to treatment in patients with high blood pressure in ambulatorysettings. Cochrane Database Syst Rev 2004; (2):CD004804.
28. Christensen A, Osterberg L, Hansen EH. Electronic monitoring ofpatient adherence to oral antihypertensive medical treatment: a systematicreview. J Hypertens 2009; 27: 1540-51.
29. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of Europeanguidelines on hypertension management: a European Societyof Hypertension Task Force document. J Hypertens 2009; 27:2121-58.
30. Feldman RD, Zou GY, Vandervoort MK, Wong CJ, Nelson SA, Feagan BG. A simplified approach to the treatment of uncomplicatedhypertension: a cluster randomized, controlled trial. Hypertension 2009; 53: 646-53.